IniXium, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
IniXium, Inc. - overview
Established
2014
Location
Laval, QC, Canada
Primary Industry
Pharmaceuticals
About
IniXium, founded in 2014 by co-founders René Coulombe and James Fethiere, is a contract research organization based in Quebec, Canada, that focuses on enhancing drug discovery processes. As of April 2024, IniXium will merge with “NuChem Sciences” and will adopt its corporate name. IniXium offers a wide range of services to the biotech and pharmaceutical industries, such as protein production, fragment screening, and the development of biologics and biosimilars. As of 2024, the firm focuses on expediting drug development with reliable scientific data, serving a variety of clients, including research institutions and corporate entities across North America, Europe, and Asia-Pacific.
Primary Industry
Pharmaceuticals
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.inixium.com
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.